Accutane / Roaccutane - Isotretinoin

accutane pills

What is Accutane and how does it work?

Accutane (also known as Isotretinoin), or Roaccutane as is also known in parts of the world, was discovered in 1979 when it was first given to patients with severe acne, most of whom reacted with dramatic and permanent clearing of their acne symptoms. It is a vitamin A derivative (13-cis-retinoic acid) which is administered orally in pill form, normally for 15-20 weeks (3.5-4.5 months). It was originally prescribed for people with severe acne that did not respond to other treatments, but has gained in popularity in the past 25 years and is prescribed more and more frequently for less severe acne. Accutane is a serious medication which must be taken under close doctor's supervision. Blood tests are required and side effects can be as devastating as they are widespread.

Exactly how Accutane works on a cellular level is unknown, but we do know that it affects all of the four ways that acne develops.

  1. It dramatically reduces the size of the skin's oil glands (35%-58%) and even more dramatically reduces the amount of oil the skin produces (around 80%).
  2. Acne bacteria (P. Acnes) lives in skin oil. Since oil is so dramatically reduced, so is the amount of acne bacteria in the skin.
  3. It also slows down how fast the skin produces skin cells inside the pore which helps pores from becoming clogged in the first place.
  4. It displays anti-inflammatory properties.

Although acne may get worse within the first month on a cycle of Accutane, the ultimate results are usually dramatic. Accutane works to achieve complete or partial clearance of acne in about 95% of people who complete a cycle, regardless of whether they have inflammatory or non-inflammatory acne. The majority of people who take it see their acne effectively cured, experiencing long term remission of acne symptoms. Studies show an average relapse rate of 25%, and in these cases sometimes a second course is given. This relapse rate is dose dependent. Patients who receive a cumulative dose of 100-120mg/kg see the best results and lowest relapse rates. Patients who receive a lower dose relapse more frequently. Depending on how much the patient weighs, .5mg - 2mg/kg is usually prescribed per day.

Accutane need not be paired with other medications. For people who have problems handling Accutane, intermittent dosage is potentially an option and is being studied for effectiveness. Generic forms of Accutane may or may not be as therapeutic or safe. This is based on only one study which was performed in the UK in 2006. Out of the 14 generic brands studied, 13 failed to match Roaccutane (as it is called in the UK) in one or more tests and 11 failed in three or more tests. More studies like this one are needed to present better data on this subject.

References

Akman A, et al. "Treatment of acne vulgaris with intermittent and conventional isotretinoin: a randomized, controlled multicenter study." Archives of Dermatological Research. 2007 Dec; 299(10): 467-73.

Al-Mutairi N., et al. "Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait." Journal of Drugs in Dermatology. 2005 May-Jun; 4(3): 369-73.

Amichai B., Shemer A, Grunwald MH. "Low-dose isotretinoin in the treatment of acne vulgaris." Journal of the American Academy of Dermatology. 2006 Apr: 54(4): 644-6.

Azoulay L, Oraichi D, Berard A. "Isotretinoin therapy and the incidence of acne relapse: a nested case-control study." British Journal of Dermatology. 2007 Dec; 157(6): 1240-8.

Chen K, et al. "Oral isotretinoin: an analysis of its utilization in a managed care organization." Journal of Managed Care Pharmacy. 2002 Jul-Aug; 8(4): 272-7.

Clearihan L. "Acne. Myths and management issues." Australian Family Physician. 2001 Nov; 30(11): 1039-44.

Coates P, et al. "Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne." British Journal of Dermatology. 2005 Dec; 153(6): 1126-36.

Dhir R, et al. "Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne." Indian Journal of Dermatology, Venereology and Leprology. 2008 Mar-Apr; 74(2): 187.

Dreno B, et al. "An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations." European Journal of Dermatology. 2006 Sep-Oct; 16(5): 565-71.

Ertam I, Alper S, Unal I. "Is it necessary to have routine blood tests in patients treated with isotretinoin?" The Journal of Dermatological Treatment. 2006: 17(4): 214-6.

Ghaffarpour G, et al. "Oral isotretinoin for acne, adjusting treatment according to patient's response." Journal of Drugs in Dermatology. 2006 Oct; 5(9): 878-82.

Ghalamkarpour F, Nasiri S. "Isotretinoin in treatment of acne: its efficacy, side effects, and recurrence rate of disease." Archives of Iranian Medicine. 2006 Jul; 9(3): 228-30.

Haryati I, Jacinto SS. "Profile of acne patients in the Philippines requiring a second course of isotretinoin." International Journal of Dermatology. 2005 Dec; 44(12): 999-1001.

Kaymak Y, et al. "Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients." Psychological Reports. 2006 Dec; 99(3): 897-906.

Kaymak Y, Ilter N. "The effectiveness of intermittent isotretinoin treatment in mild or moderate acne." Journal of the European Academy of Dermatology and Venereology. 2006 Nov; 20(10): 1256-60.

Mandekou-Lefaki I, et al. "Low-dose schema of isotretinoin in acne vulgaris." International Journal of Clinical Pharmacological Research. 2003; 23(2-3): 41-6.

Nelson AM, et al. "13-cis-retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes." Journal of Investigative Dermatology. 2006 Oct; 126(10): 2178-89.

Ng PP, Goh CL. "Treatment outcome of acne vulgaris with oral isotretinoin in 89 patients." International Journal of Dermatology. 1999 Mar; 38(3): 213-6.

Plewig G, et al. "Low dose isotretinoin combined with tretinoin is effective to correct abnormalities in acne." Journal of the German Society of Dermatology. 2004 Jan; 2(1): 31-45.

Quereux G, et al. "Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin." Dermatology. 2006; 212(2): 168-76.

Schroeder M, Zouboulis CC. "All-trans-retinoic acid and 13-cis-retinoic acid: Pharmacokinetics and biological activity in different cell culture models of human keratinocytes." Hormone and Metabolic Research. 2007 Feb; 39(2): 136-40.

Taylor PW, Keenan MH. "Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane." Current Medical Research and Opinion. 2006 Mar; 22(3): 603-15.

Wysowski DK, Swann J, Vega A. "Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000." Journal of the American Academy of Dermatology. 2002 Apr; 46(4): 505-9.

Zaghioul SS, Cunliffe WJ, Goodfield MJ. "Objective assessment of compliance with treatments in acne." British Journal of Dermatology. 2005 May; 152(5): 1015-21.